Table 2.
Pathway analysis using the PG2-enriched signature (top 30 pathways).
| Pathway | Source | #Genes in set | p value | q-value | Overlap | Immune | cancer |
|---|---|---|---|---|---|---|---|
| Immune system | Reactome | 1011 | 2.16939E − 11 | 3.90490E − 09 | 28 | □ | |
| Pathways in cancer | KEGG | 327 | 3.68916E − 09 | 3.32025E − 07 | 15 | □ | |
| NF-kappa B signaling pathway | KEGG | 92 | 1.01889E − 08 | 6.11336E − 07 | 9 | □ | □ |
| Hepatitis C | KEGG | 133 | 1.90274E − 08 | 8.56232E − 07 | 10 | ||
| Cytokine signaling in immune system | Reactome | 186 | 4.29066E − 08 | 1.41014E − 06 | 11 | □ | |
| Signaling events mediated by stem cell factor receptor (c-Kit) | PID | 53 | 5.95581E − 08 | 1.41014E − 06 | 7 | □ | □ |
| RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | Reactome | 53 | 5.95581E − 08 | 1.41014E − 06 | 7 | □ | |
| IL2 signaling events mediated by STAT5 | PID | 32 | 6.26727E − 08 | 1.41014E − 06 | 6 | □ | □ |
| EPO signaling pathway | PID | 34 | 9.20249E − 08 | 1.8405E − 06 | 6 | □ | |
| Epstein-Barr virus infection | KEGG | 204 | 1.10634E − 07 | 1.99141E − 06 | 11 | ||
| Neurotrophic factor-mediated Trk receptor signaling | PID | 65 | 2.52184E − 07 | 4.09444E − 06 | 7 | □ | |
| Measles | KEGG | 134 | 2.72963E − 07 | 4.09444E − 06 | 9 | □ | |
| TRAF3-dependent IRF activation pathway | Reactome | 13 | 1.33772E − 06 | 1.71993E − 05 | 4 | □ | |
| Signaling events mediated by hepatocyte growth factor receptor (c-Met) | PID | 84 | 1.48134E − 06 | 1.77760E − 05 | 7 | □ | |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | Reactome | 15 | 2.52771E − 06 | 2.84368E − 05 | 4 | □ | □ |
| MyD88-independent cascade | Reactome | 97 | 3.91774E − 06 | 3.71155E − 05 | 7 | □ | |
| Toll-like receptor 3 (TLR3) cascade | Reactome | 97 | 3.91774E − 06 | 3.71155E − 05 | 7 | □ | □ |
| Beta-catenin phosphorylation cascade | Reactome | 17 | 4.36224E − 06 | 3.92601E − 05 | 4 | □ | □ |
| Platelet sensitization by LDL | Reactome | 18 | 5.57985E − 06 | 4.78273E − 05 | 4 | □ | |
| Interferon signaling | Reactome | 69 | 6.80349E − 06 | 5.56649E − 05 | 6 | □ | □ |
| Signaling events mediated by TCPTP | PID | 41 | 7.79283E − 06 | 6.03140E − 05 | 5 | □ | □ |
| RIG-I-like receptor signaling pathway | KEGG | 71 | 8.04187E − 06 | 6.03140E − 05 | 6 | □ | □ |
| Chronic myeloid leukemia | KEGG | 73 | 9.45705E − 06 | 6.65100E − 05 | 6 | □ | □ |
| Activated TLR4 signaling | Reactome | 111 | 9.60700E − 06 | 6.65100E − 05 | 7 | □ | □ |
| Negative regulators of RIG-I/MDA5 signaling | Reactome | 21 | 1.07467E − 05 | 7.16445E − 05 | 4 | ||
| Signaling by interleukins | Reactome | 114 | 1.14527E − 05 | 7.36243E − 05 | 7 | □ | □ |
| Inhibition of cellular proliferation by Gleevec | PID | 22 | 1.30676E − 05 | 8.11090E − 05 | 4 | □ | □ |
| Interleukin-3, interleukin-5, and GM-CSF signaling | Reactome | 47 | 1.54549E − 05 | 8.74477E − 05 | 5 | □ | |
| CTLA4 inhibitory signaling | Reactome | 23 | 1.57376E − 05 | 8.74477E − 05 | 4 | □ | |
| Neurotrophin signaling pathway | KEGG | 120 | 1.60321E − 05 | 8.74477E − 05 | 7 |